Stock LCTX LINEAGE CELL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.14 USD +2.70% Intraday chart for Lineage Cell Therapeutics, Inc. -0.87% +4.59%
Mar. 11 Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting CI
Mar. 07 Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
BU
Lineage Cell Therapeutics : Immediate Report
PU
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
BU
LINEAGE CELL THERAPEUTICS, INC. - RG6501 PHASE 1/2A CLINICAL STUDY 24 MONTH RESULTS TO BE FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT
AQ
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
BU
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
BU
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting
CI
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Samuel George A. III
PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Cukkey Brian M
PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Howe Jill Ann
PU
Lineage Cell Therapeutics : FORM S-3-Registration Statements
PU
Lineage Cell Therapeutics : Annual report which provides a comprehensive overview of the company for the past year
PU
Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q4 Revenue $8.9M, vs. Street Est of $2.8M
MT
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
BU
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
BU
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
BU
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury
CI
LINEAGE CELL THERAPEUTICS ANNOUNCES CLOSING OF $14.0 MILLION REGISTERED DIRECT OFFERING
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LCTX Stock
  4. News Lineage Cell Therapeutics, Inc.